Skip to main content

Andrew T. Lucas

Andrew T. Lucas, PharmD, MS is a UNC Lineberger Comprehensive Cancer Center member and an Assistant Professor in the UNC School of Pharmacy – Division of Pharmacotherapy & Experimental Therapeutics.

PharmD, MS
Assistant Professor
UNC-Chapel Hill

Area of interest

In translational and clinical pharmacology, the ability to work collaboratively in a multi-disciplinary environment is important. I have been involved in cancer research for nearly twelve years and translational/clinical studies of anti-cancer agents for the past eight years. As a trained pharmacist, I am intrigued by the interconnections between the drug’s pharmacology, pharmacokinetics (PK), and pharmacodynamics (PD), and their impact on efficacy and toxicity, especially as I consider these factors for bedside patient care. During my career, I want to improve the lives of patients by contributing to our current understanding of drug toxicity, pharmacokinetics, and early detection of a patient’s response; translating exceptional benchtop science into patient survival.

A focus of my current research program as part of the Translational Oncology and Nanoparticle Drug Development Initiative (TONDDI) Lab and is involved in the translational studies of anti-cancer agents. This research focuses on the application of clinical pharmacology with PK/PD principles in the optimization of the treatment of cancer. My primary focus has been in the evaluation of PK and PD differences of therapeutic proteins (e.g. monoclonal antibodies, PEGylated therapeutic proteins) and carrier-mediated agent (CMA; e.g. nanoparticles, antibody-drug conjugates) comparing the PK (concentration versus time) and PD (efficacy and toxicity). A second focus of my research is in the development of phenotypic probes and screens of the innate immune system as a means to translate factors known to contribute to inter-patient PK/PD variability into clinical practice in order to create new paradigms to individualize therapy. Further, by probing the relationship between the PK/PD of these agents and the innate immune system, we can attempt to predict outcomes (both efficacy and/or toxicity) of the use of these agents.

Awards and Honors

  • Associate Member, Clinical Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 2018 to present.
  • Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC, 2017 to present.

Find publications on Pubmed